Effects of the Interaction of the ANKK1/DRD2 TaqIA and HTR2C Cys23Ser Polymorphisms on Approach Motivation in Schizophrenia Patients and Healthy People
- 4 Downloads
Objective. To assess the association of the DRD2 gene and its interaction with the HTR2C gene with the characteristics of the hedonistic and activatory aspects of approach motivation in schizophrenia. Materials and methods. Genotypes at the polymorphic loci rs1800497 of DRD2 and rs6318 (Cys23Ser) of HTR2C were identified in a cohort including 174 patients with schizophrenia spectrum disorders and 268 healthy subjects. Subjects completed scales assessing approach motivation (BIS/BAS) and the Temporal Experience of Pleasure Scale (TEPS). Results and conclusions. Analysis taking account of sex and age identified an effect of the interaction between the DRD2 and HTR2C genes and diagnosis (p = 0.033) on assessments on the BAS scales. The effect was significant on the Fun-Seeking and Drive subscales. Among patients, the highest scores on both scales were seen with the combination of the DRD2 TT/CT and HTR2C GG/G genotypes and the lowest in carriers of the diplotypes with the minor alleles at both loci. Differences between these group were nominally significant for both scales, but were not significant after correction for multiple comparisons. Among healthy subjects, the highest levels of motivation were seen in people lacking the minor alleles. They were significantly different from those in carriers of the DRD2 TT/CT and HTR2C GG/G diplotype on the Fun-Seeking subscale (pcorr = 0.008). DRD2 and HTR2C were not found to have any effect on TEPS evaluations. Our results can be interpreted as indicating a role for the interaction of the DRD2 and HTR2C genes in the variation of the activatory aspects of approach motivation in both schizophrenia patients and healthy subjects. However, the absence of highly significant (persisting after the Bonferroni correction) differences between groups with different diplotypes makes it difficult to interpret this effect.
Keywordspsychosis motivation pleasure dopamine serotonin genetic polymorphism intergene interaction
Unable to display preview. Download preview PDF.
- 4.A. O. Kibitov, “The genetics of addiction diseases: molecular genetic profile of the dopamine neurotransmitter system in alcoholism and opioid addiction,” Narkologiya, 10, No. 9, 25–42 (2011).Google Scholar
- 10.A. Richter, A. Barman, T. Wustenberg, et al., “Behavioral and neural manifestations of reward memory in carriers of low-expressing versus high-expressing genetic variants of the dopamine D2 receptor,” Front. Psychol., 8, 654 (2017), https://doi.org/ https://doi.org/10.3389/fpsyg.2017.00654.
- 11.M. Reuter, A. Schmitz, P. Corr, and J. Hennig, “Molecular genetics support Gray’s personality theory: The interaction of COMT and DRD2 polymorphisms predicts the behavioural approach system,” Int. J. Neuropsychopharmacol., 9, No. 2, 155–166 (2006), https://doi.org/ https://doi.org/10.1017/S1461145705005419.CrossRefGoogle Scholar
- 12.S. H. Lee, B. J. Ham, Y. H. Cho, et al., “Association study of dopamine receptor D2 TaqIA polymorphism and reward-related personality traits in healthy Korean young females,” Neuropsychobiology, 56, No. 23, 146–151 (2007), https://doi.org/ https://doi.org/10.1159/000115781.
- 13.C. Davis, R. D. Levitan, A. S. Kaplan, et al., “Reward sensitivity and the D2 dopamine receptor gene: A case-control study of binge eating disorder,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, No. 3, 620–628 (2008), https://doi.org/ https://doi.org/10.1016/j.pnpbp.2007.09.024.CrossRefGoogle Scholar
- 16.Schizophrenia Working Group of the Psychiatric Genomics Consortium, “Biological insights from 108 schizophrenia-Associated geof netic loci,” Nature, 511, No. 7510, 421–427 (2014), https://doi.org/10.1038/nature13595\.Google Scholar
- 17.R. Brisch, A. Saniotis, R. Wolf, et al., “The Role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue,” Front. Psychiatry, 5, 47 (2014), https://doi.org/ https://doi.org/10.3389/fpsyt.2014.00047.
- 19.S. G. Kang, K. S. Na, H. J. Lee, et al., “DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks’ amisulpride treatment,” J. Clin. Psychopharmacol., 35, No. 2, 158–162 (2015), https://doi.org/ https://doi.org/10.1097/JCP.0000000000000294.CrossRefGoogle Scholar
- 20.S. A. Eisenstein, R. Bogdan, L. Chen, et al., “Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia,” J. Psychiatr. Res., 86, 9–17 (2017), https://doi.org/ https://doi.org/10.1016/j.jpsychires.2016.11.007.CrossRefGoogle Scholar
- 28.T. Sumiyoshi, H. Kunugi, and K. Nakagome, “Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia,” Front. Neurosci., 8, 395 (2014), https://doi.org/ https://doi.org/10.3389/fnins.2014.00395.
- 33.M. V. Alfimova, V. E. Golimbet, G. I. Korovaitseva, et al., “Association of the Cys23Ser polymorphism of the type 2C serotonin receptor gene with social behavior in schizophrenia patients and healthy subjects,” Genetika, 51, No. 2, 242–247 (2015), https://doi.org/ https://doi.org/10.1134/S1022795415010020].CrossRefGoogle Scholar
- 34.J. A. Beeler, R. P. Faust, S. Turkson, et al., “Low dopamine D2 receptor increases vulnerability to obesity via reduced physical activity not increased appetitive motivation,” Biol. Psychiatry, 79, No. 11, 887–897 (2016), https://doi.org/ https://doi.org/10.1016/j.biopsych.2015.07.009.CrossRefGoogle Scholar
- 37.B. H. Brummett, M. A. Babyak, R. B. Williams, et al., “A putatively functional polymorphism in the HTR2C gene is associated with depressive symptoms in white females reporting signifi cant life stress,” PLoS One, 9, No. 12, 114451 (2014), https://doi.org/ https://doi.org/10.1371/journal.pone.0114451.CrossRefGoogle Scholar
- 38.N. M. Vyalova, I. V. Pozhidaev, D. Z. Osmanova, et al., “Association of polymorphic variants of the PIP5K2A and HTR2C genes with antidepressant treatment effi cacy in patients with prolonged depressive episode,” Zh. Nevrol. Psikhiat., 117, No. 5, 58–61 (2017), https://doi.org/ https://doi.org/10.17116/jnevro20171175158-61.CrossRefGoogle Scholar
- 39.M. V. Alfimova, T. V. Lezheiko, G. I. Korovaitseva, and V. E. Golimbet, “Psychological and molecular genetic mechanisms of decreases in Machiavellianism in schizophrenia,” Zh. Vyssh. Shkol. Ekonom., 12, No. 2, 70–92 (2015).Google Scholar
- 40.A. C. Katz, C. Sarapas, J. R. Bishop, et al., “The mediating effect of prefrontal asymmetry on the relationship between the COMT Val158Met SNP and trait consummatory positive affect,” Cogn. Emot., 29, No. 5, 867–881 (2015), https://doi.org/ https://doi.org/10.1080/02699931.2014.951030.CrossRefGoogle Scholar
- 41.S. A. Eisenstein, R. Bogdan, L. Chen, et al., “Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia,” J. Psychiatr. Res., 86, 9–17 (2017), https://doi.org/ https://doi.org/10.1016/j.jpsychires.2016.11.007.CrossRefGoogle Scholar